News All of Ferrer’s information, just a click away Home News normal Apply Ferrer and Prilenia Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS . Mon, 03/30/2026 - 07:26 Ferrer included in the ranking of the World’s Most Ethical Companies® in 2026 . Wed, 03/18/2026 - 12:05 We complete recruitment of 220 patients for the PROSPER study, a Phase II clinical trial in progressive supranuclear palsy (PSP), two months ahead of schedule . Tue, 10/21/2025 - 08:32 Nature Medicine Publishes Phase 3 Data on Pridopidine in Early-Stage Huntington’s Disease, Highlighting Impact on Clinical Progression . Fri, 09/05/2025 - 08:15 Prilenia and Ferrer Provide Update on European Regulatory Process for Pridopidine in Huntington’s Disease . Fri, 07/25/2025 - 09:55 Ferrer strengthens its impact in 2024 with increased social and environmental investment, B Corp leadership and sustainability progress . Mon, 07/21/2025 - 17:01 We Receive FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP) . Tue, 06/17/2025 - 07:06 We enter into a collaboration and license agreement with Prilenia for the commercialization and co-development of Pridopidine . Mon, 04/28/2025 - 09:38 Experts Set International and Multidisciplinary Collaboration As Priorities in Pulmonary Hypertension Management . Wed, 04/23/2025 - 10:23 We are the highest-rated pharma B Corp in the world . Thu, 02/20/2025 - 17:03 Cargar más For requests for interviews or information, please contact the Communications Department CONTACT US alternatively, please dial +34 936 003 779 See more R&D Strategy Business Development
Ferrer and Prilenia Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS . Mon, 03/30/2026 - 07:26
Ferrer included in the ranking of the World’s Most Ethical Companies® in 2026 . Wed, 03/18/2026 - 12:05
We complete recruitment of 220 patients for the PROSPER study, a Phase II clinical trial in progressive supranuclear palsy (PSP), two months ahead of schedule . Tue, 10/21/2025 - 08:32
Nature Medicine Publishes Phase 3 Data on Pridopidine in Early-Stage Huntington’s Disease, Highlighting Impact on Clinical Progression . Fri, 09/05/2025 - 08:15
Prilenia and Ferrer Provide Update on European Regulatory Process for Pridopidine in Huntington’s Disease . Fri, 07/25/2025 - 09:55
Ferrer strengthens its impact in 2024 with increased social and environmental investment, B Corp leadership and sustainability progress . Mon, 07/21/2025 - 17:01
We Receive FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP) . Tue, 06/17/2025 - 07:06
We enter into a collaboration and license agreement with Prilenia for the commercialization and co-development of Pridopidine . Mon, 04/28/2025 - 09:38
Experts Set International and Multidisciplinary Collaboration As Priorities in Pulmonary Hypertension Management . Wed, 04/23/2025 - 10:23